K2 VBI Equity Trust, LLC acquires VBI Vaccines Inc. (2025)

Deal facts

Buyer: K2 VBI Equity Trust, LLC
Target: VBI Vaccines Inc.
Deal value: Not disclosed
Announced: 3 January 2025
Status: Completed
Sector: Healthcare
Country: Canada
Consideration: shares

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

3 Jan 2025CompletedClosed
K2 VBI Equity Trust, LLC completes acquisition of VBI Vaccines Inc.
Item 2.01. Completion of Acquisition or Disposition of Assets As previously disclosed, on July 30, 2024, VBI Vaccines Inc. (the “ Company ”) and its subsidiaries commenced voluntary restructuring under the jurisdiction of the Ontario Superior Court of Justice (Commercial List) (the “ Court ”) pursuant to the Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the “ CCAA ”). On
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of VBI Vaccines Inc by K2 VBI Equity Trust, LLC. This transaction, announced on 3 January 2025, marks a definitive shift from public markets to private ownership for a Canadian healthcare firm. The deal structure is a classic going-private move where the consideration consists entirely of shares in the acquiring entity. There is no cash component disclosed, which places the entire value proposition on the future equity performance of the new private vehicle. This mechanism removes the quarterly earnings pressure that often constrains long-term biotech strategy, yet it also transfers market liquidity risk directly to the selling shareholders.

The cross-border nature of this deal, moving a Canadian target into a US private trust, introduces specific regulatory and commercial mechanics that the SME founder must respect. While the deal is already marked as completed, the path to this finish line almost certainly required scrutiny under Canadian competition laws and potentially US anti-trust thresholds given the healthcare sector sensitivity. For founders in similar positions, the reliance on share-based consideration in a going-private scenario means the exit is not truly final until the new shares are liquid or listed. This structure often includes change-of-control covenants that lock up capital for extended periods, a reality that differs sharply from a cash buyout.

We think this move highlights a growing trend where specialised trusts are stepping in to provide an exit route when public valuations fail to reflect underlying scientific progress. The absence of a disclosed monetary value in the announcement underscores the complexity of valuing pre-revenue or early-stage biotech assets in a private setting. For the SME founder watching this space, the lesson is about understanding the liquidity profile of your exit. A share-only deal in a private trust offers strategic freedom but demands a clear plan for how and when you will realise value from those new holdings.

Your immediate action this week should be to audit the liquidity terms of any current or potential exit proposal. If a buyer offers only equity in a private vehicle, demand a written schedule outlining the specific conditions and timelines required to convert those shares into cash or a public listing. Do not sign a deal based on the promise of future value without a defined mechanism for exit from the private structure itself.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from K2 VBI Equity Trust, LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

6 July 2026CompletedHealthcare

Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.

Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…

Buyer: Trafalgar Asset Management, LLC
Target: The Greater Cannabis Company, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 June 2026CompletedHealthcare

Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.

Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…

Buyer: Hanmi Pharmaceuticals Co. Ltd.
Target: Aptose Biosciences Inc.
Deal value: USD 3,466,470
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

9 June 2026CompletedHealthcare

GlaxoSmithKline LLC to acquire Nuvalent, Inc.

GlaxoSmithKline LLC has agreed to acquire Nuvalent, Inc. in a going private transaction. The deal was announced on 9 June 2026 and completed on 15 July 2026. The conside…

Buyer: GlaxoSmithKline LLC
Target: Nuvalent, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

3 June 2026CompletedHealthcare

FONAR, LLC to acquire FONAR Corporation

FONAR, LLC has agreed to acquire FONAR Corporation in a going private transaction completed on 3 June 2026. The deal involves the purchase of the US-based healthcare com…

Buyer: FONAR, LLC
Target: FONAR Corporation
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

13 May 2026CompletedHealthcare

Zydus Worldwide DMCC to acquire Assertio Holdings, Inc.

Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, wa…

Buyer: Zydus Worldwide DMCC
Target: Assertio Holdings, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history